https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-and-epicentrx-announce-strategic-research-collaboration
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-72-mrd-negativity-rate-in-the-recently
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-reports-2-remissions-and-67-orr-in-patients-with-a-tp53
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-greater-difference-of-approximately-5x-for
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-participation-in-two-panel-discussions-at-the
https://www.nasdaq.com/press-release/actinium-presents-first-ever-data-with-a-cd47-immunotherapy-in-combination-with-a
https://www.nasdaq.com/press-release/actinium-highlights-actimab-a-combined-with-cd47-immunotherapy-results-in
https://www.nasdaq.com/press-release/actinium-announces-completion-of-enrollment-of-actimab-a-clag-m-combination-trial-in
https://www.nasdaq.com/press-release/actinium-announces-multiple-abstracts-highlighting-iomab-b-and-actimab-a-accepted-for
https://www.nasdaq.com/press-release/actinium-announces-two-abstracts-highlighting-combinations-of-cd47-targeting
https://www.nasdaq.com/press-release/actinium-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-on
https://www.nasdaq.com/press-release/actinium-announces-expansion-of-rd-team-and-facilities-to-accelerate-research
https://www.nasdaq.com/press-release/actinium-announces-multiple-senior-leadership-appointments-including-chief-business
https://www.nasdaq.com/press-release/actinium-to-present-at-four-upcoming-investor-conferences-2021-09-20
https://www.nasdaq.com/press-release/actinium-completes-enrollment-in-the-pivotal-phase-3-sierra-trial-of-iomab-b-2021-09
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-announces-inclusion-in-russell-microcapr-index-2021-06-28
https://www.nasdaq.com/press-release/actinium-further-strengthens-patent-portfolio-with-international-ip-covering-the
https://www.nasdaq.com/press-release/pivotal-phase-3-sierra-trial-data-showing-100-bone-marrow-transplant-engraftment-in
https://www.nasdaq.com/press-release/safety-data-highlighting-low-rates-of-adverse-events-and-non-relapse-transplant
https://www.nasdaq.com/press-release/actinium-announces-several-presentations-from-the-phase-3-sierra-study-of-iomab-b-at
https://www.nasdaq.com/press-release/actinium-to-participate-in-the-cell-gene-meeting-on-the-mediterranean-2021-03-31
https://www.nasdaq.com/press-release/actinium-announces-completion-of-enrollment-of-second-dose-cohort-in-actimab-a
https://www.nasdaq.com/press-release/actinium-announces-initiation-of-patient-enrollment-in-iomab-act-trial-for-targeted
https://www.nasdaq.com/press-release/actinium-to-highlight-expansion-of-targeted-conditioning-portfolio-at-aacr-with-next
https://www.nasdaq.com/press-release/actinium-announces-appointment-of-mark-kubik-mba-as-chief-business-officer-2021-03-03
https://www.nasdaq.com/press-release/actinium-announces-participation-in-h.c.-wainwright-global-life-sciences-conference
https://www.nasdaq.com/press-release/actinium-showcases-targeted-conditioning-program-with-2-oral-presentations
https://www.nasdaq.com/press-release/actinium-announces-participation-in-bio-ceo-investor-digital-conference-2021-02-10
https://www.nasdaq.com/press-release/actinium-to-participate-in-a-fireside-chat-at-the-b.-riley-oncology-investor
https://www.nasdaq.com/press-release/actinium-and-astellas-announce-research-collaboration-focused-on-novel-actinium-225
https://www.nasdaq.com/press-release/actinium-announces-successful-pre-planned-ad-hoc-interim-analysis-of-phase-3-sierra
https://www.nasdaq.com/press-release/actinium-highlights-presence-at-targeted-radiopharmaceuticals-summit-2020-12-09
https://www.nasdaq.com/press-release/actinium-reports-67-percent-overall-response-rate-in-first-cohort-in-actimab-a
https://www.nasdaq.com/press-release/actinium-announces-positive-interim-results-from-iomab-b-pivotal-phase-3-sierra-0
https://www.nasdaq.com/press-release/actinium-highlights-iomab-b-safety-data-presented-at-the-62nd-american-society-of
https://www.nasdaq.com/press-release/actinium-presents-interim-data-from-actimab-a-clag-m-phase-1-combination-trial-at-the
https://www.nasdaq.com/press-release/actinium-highlights-clinical-data-to-be-presented-at-the-upcoming-62nd-american
https://www.nasdaq.com/press-release/actinium-appoints-mary-mei-chen-m.d.-ph.d.-as-vice-president-of-clinical-development
https://www.nasdaq.com/press-release/actinium-highlights-foundational-patents-covering-the-composition-of-apamistamab
https://www.nasdaq.com/press-release/actinium-strengthens-leadership-team-with-appointment-of-dr.-avinash-desai-as
https://www.nasdaq.com/press-release/actinium-to-participate-in-the-alliance-global-partners-virtual-healthcare-symposium
https://www.nasdaq.com/press-release/actinium-to-host-kol-call-on-november-11th-featuring-actimab-a-aml-combination-trials
https://www.nasdaq.com/press-release/100-remission-rate-reported-in-third-dose-cohort-of-actimab-a-clag-m-phase-1
https://www.nasdaq.com/press-release/actinium-announces-two-oral-presentations-featuring-data-and-findings-from-the-phase
https://www.nasdaq.com/press-release/actinium-announces-actimab-a-venetoclax-first-in-human-data-accepted-for-poster
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-provides-corporate-update-and-year-end-2020-outlook
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-awarded-grant-by-national-institutes-of-health-to-study
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-expands-rd-capabilities-with-new-research-facility-to
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-clinical-trial-site-expansion-in-its-multi
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-successfully-completes-first-dosing-cohort-in-the-phase-1
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-announces-successful-completion-of-planned-phase-1-actimab-a
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-to-present-at-the-22nd-annual-h.c.-wainwright-global
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-reverse-stock-split-2020-08-10
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-closing-of-%2425.0-million-public-offering-2020
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-pricing-of-%2425.0-million-public-offering-2020
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-proposed-public-offering-2020-06-16
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-closing-of-%2431.6-million-public-offering
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-pricing-of-%2427.5-million-public-offering-2020
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-announces-proposed-public-offering-2020-04-21
https://www.nasdaq.com/press-release/actinium-provides-update-on-iomab-b-sierra-trial-and-expected-topline-results-from-ad
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-announces-first-patient-treated-in-third-and-final-dose
https://www.nasdaq.com/press-release/actinium-announces-actimab-a-plus-73-combination-trial-for-newly-diagnosed-acute
https://www.nasdaq.com/press-release/actinium-presents-positive-findings-from-mid-point-analysis-of-pivotal-sierra-trial
https://www.nasdaq.com/press-release/actinium-to-highlight-targeted-conditioning-portfolio-at-2020-transplantation
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-to-present-at-the-22nd-annual-bio-ceo-investor
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-announces-iomab-act-program-gene-therapy-collaboration-with
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-inc.-to-present-at-2020-biotech-showcasetm-2020-01-07
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-to-present-at-the-25th-annual-bio-europer-2019-international
https://www.nasdaq.com/press-release/actinium-announces-interim-results-from-phase-1-actimab-a-clag-m-combination-trial-in
https://www.nasdaq.com/press-release/actinium-pharmaceuticals-to-present-new-clinical-findings-from-sierra-trial
https://www.nasdaq.com/press-release/actinium-announces-positive-interim-results-from-iomab-b-pivotal-phase-3-sierra-trial
